Hsbc Holdings PLC Bio N Tech Se Transaction History

Hsbc Holdings PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$122.57 - $153.67 $4,412 - $5,532	36 Added 2.01%	1,824 $227,000
Q4 2022 Feb 14, 2023	SELL	$118.43 - $186.05 $53,056 - $83,350	-448 Reduced 20.04%	1,788 $268,000
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $3.78 Million - $5.43 Million	-29,634 Reduced 92.98%	2,236 $304,000
Q2 2022 Aug 11, 2022	BUY	$123.25 - $186.24 $3.2 Million - $4.84 Million	25,985 Added 441.55%	31,870 $4.83 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $575,447 - $1.06 Million	4,558 Added 343.48%	5,885 $1.01 Million
Q4 2021 Feb 11, 2022	SELL	$216.64 - $362.52 $1.38 Million - $2.32 Million	-6,386 Reduced 82.8%	1,327 $342,000
Q3 2021 Nov 12, 2021	BUY	$205.93 - $447.23 $638,794 - $1.39 Million	3,102 Added 67.27%	7,713 $2.13 Million
Q2 2021 Aug 13, 2021	SELL	$113.32 - $241.49 $171,906 - $366,340	-1,517 Reduced 24.76%	4,611 $1.03 Million
Q1 2021 May 14, 2021	SELL	$85.73 - $119.5 $995,582 - $1.39 Million	-11,613 Reduced 65.46%	6,128 $669,000
Q4 2020 Feb 12, 2021	SELL	$72.71 - $129.54 $3.56 Million - $6.34 Million	-48,916 Reduced 73.38%	17,741 $1.45 Million
Q3 2020 Nov 12, 2020	BUY	$57.81 - $104.17 $3.85 Million - $6.94 Million	66,657 New	66,657 $4.6 Million

358

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $24.2B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.